Abeona therapeutics announces presentation on pivotal transpher a study of abo-102 in mps iiia at the 14th iciem conference

New york and cleveland, nov. 17, 2021 (globe newswire) -- abeona therapeutics inc. (nasdaq: abeo), a fully-integrated leader in gene and cell therapy, today announced that information about the company's abo-102 pivotal transpher a study in sanfilippo syndrome type a (mps iiia) will be presented at the 14th international congress of inborn errors of metabolism (iciem). the meeting will take place virtually and at the hilton sydney in sydney, australia on november 21-23, 2021.
ABEO Ratings Summary
ABEO Quant Ranking